Post hoc analyses of GOG 9923: Does BRCA status affect toxicities?: An NRG oncology study

Jessica Gillen,Austin Miller,Katherine M Bell-McGuinn,Russell J Schilder,Joan L Walker,Cara A Mathews,Linda R Duska,Saketh R Guntupalli,Roisin O'Cearbhaill,John Hays,Andrea R Hagemann,Heidi J Gray,Sarah W Gordon,Deborah K Armstrong,Alice Chen,Paula M Fracasso,Carol Aghajanian,Kathleen N Moore

Gynecologic Oncology（2021）

引用 3|浏览23

暂无评分

摘要

•BRCA status does not affect hematologic AEs experienced by women receiving cytotoxic therapy with bevacizumab and veliparib.•Rates of non-hematologic and hematologic AEs were similar between all 3 regimens.•Rates of hematologic AEs were similar between continuous and intermittent veliparib dosing.•Median progression free survival was not significantly different between BRCA associated and wild type cancers.

查看译文

关键词

Post hoc analyses,BRCA,Toxicities,Epithelial ovarian cancer

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要